BioCurex’s Novel Test Using Their Patented RECAF™ Technology, May Detect Cancer Earlier, Surpassing Other Tests Available
BioCurex is a cancer research and development company that has developed a method of cancer detection surpassing others in the field with the use of their patented RECAF™ technology.
With the said test, scientists at BioCurex can differentiate cancer cells from healthy cells in ways that previous scientists have been unable to do.
According to Dr. Moro-Vidal, BioCurex’s President and CEO:
“Cancer markers help distinguish cancer cells from non-cancerous cells. The ideal marker is a molecule that’s present in all cancer cells of all tissue types — none of the present markers can do that; and RECAF is the only one discovered to date that comes very close to that ideal.”
Cancer markers are actually molecules found in human cells that identify certain cellular characteristics.
By notating whether markers are present or not, scientists are able to determine whether a cell is normal, benign, or cancerous.
The best cancer markers to date (AFP, CEA, PSA, and Ca125) have been in many ways effective in identifying cancer. BUT, these tests are limited by their ability to identify cancer only in certain organs.
RECAF, on the other hand, works across the board, showing very high sensitivity and specificity in all cancers so far studied, including lung, breast, prostate, ovarian, cervical, colorectal, stomach and others. These types represent the vast majority of all cancers.
BioCurex presented its results on blood testing for cancer detection at the annual meeting of the International Society for Oncofetal Biology and Medicine, which revealed that the company’s RECAF™ test detected twice the amount of cancer than PSA.
Read the full press release.
Tags: AFP, BioCurex, Ca125, cancer-detection-test, CEA, PSA, RECAFRelated Stories
POSTED IN: on cancer diagnostics
0 opinions for BioCurex’s Novel Test Using Their Patented RECAF™ Technology, May Detect Cancer Earlier, Surpassing Other Tests Available
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: